Clinical trials: Her 2 Positive Breast Cancer
Her 2 Positive Breast Cancer
Strain Imaging in Breast Cancer Patients Receiving Trastuzumab
The purpose of this research study is to evaluate the effects of the chemotherapeutic drug, Trastuzumab (Herceptin) on the heart.
- Trial name
- NCT02080390
- Testing
- Transthoracic echocardiogram (ultrasound)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Florida
HER-2 Positive Breast Cancer
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
Purpose: This study is a single-arm, open-label phase II clinical trial testing the hypothesis that daily everolimus plus weekly vinorelbine and trastuzumab will be effective, safe, and tolerable among patients with human…
- Trial name
- NCT01305941
- Testing
- Everolimus, Vinorelbine, Trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Human Epithelial Receptor (HER)-2 Positive Breast Cancer
A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients
BCD-022-02 is a double-blind randomized clinical trial comparing efficacy of BCD-022 (INN: trastuzumab) and paclitaxel to Herceptin and paclitaxel in HER2-positive metastatic breast cancer with pharmacokinetics substudy.
- Trial name
- NCT01764022
- Testing
- Trastuzumab, Paclitaxel
- Where
- 36 sites in Belarus, India and 2 more
- Volunteers
- 225 people
- Sponsor
- Biocad
Breast Cancer, Metastatic Breast Cancer
AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer
The purpose of this study is to find out what effects, administering infusions of AUY922 with hormonal therapy (letrozole) and oral targeted drug (lapatinib) will have on the patients with advanced breast cancer known as ER+ HER2…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, HER-2 Positive Breast Cancer, ER Positive Breast Cancer
- Trial name
- NCT01361945
- Testing
- AUY922
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Breast Cancer, HER-2 Positive Breast Cancer
Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer
There is major concern regarding chemotherapy related toxicity in the group of women older than 65 years old diagnosed with human epidermal growth factor receptor 2 (HER2) positive breast cancer (BC).
- Trial name
- NCT02102438
- Testing
- Trastuzumab, Weekly Paclitaxel, Carboplatin
- Where
- Brazil
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II
Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Study participants with primary breast cancer will receive a standard chemotherapy with an anthracycline and a taxane as well as trastuzumab in case of HER2-positive tumors at doses and duration in concordance to current…
- Conditions
- Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer
- Trial name
- GeparSixto (NCT01426880)
- Testing
- Carboplatin, background treatment
- Where
- 3 sites in Germany
- Volunteers
- 595 people
- Sponsor
- GBG Forschungs GmbH
HER-2 Positive Breast Cancer, Malignant Neoplasm of Breast
A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer
A Phase Ib Study of Lapatinib in Combination with Caelyx in Patients with Advanced HER2 positive pretreated Breast Cancer. Treatment Plan: Lapatinib is given at escalating doses orally and continuously on days 1-21.
- Trial name
- CAELYX (NCT02131506)
- Testing
- Lapatinib, Caelyx
- Where
- Italy
- Volunteers
- 11 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Breast Cancer, HER-2 Positive Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
The purpose of this study is to determine if ganetespib (STA-9090) is effective in the treatment of patients with HER2+ or triple negative breast cancer who have not received prior systemic treatment in the metastatic setting.
- Conditions
- Breast Cancer, HER-2 Positive Breast Cancer, Triple Negative Breast Cancer, ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment
- Trial name
- Enchant (NCT01677455)
- Testing
- ganetespib
- Where
- 25 sites in United States, Argentina and 6 more
- Volunteers
- 51 people
- Sponsor
- Synta Pharmaceuticals Corp.
HER-2 Positive Breast Cancer
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
This study will evaluate the safety and efficacy of eribulin in combination with carboplatin and trastuzumab in the neoadjuvant setting in subjects who are human epidermal growth factor receptor (HER)2 positive and are clinically…
- Trial name
- NCT01388647
- Testing
- eribulin, carboplatin, trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Vector Oncology
Metastatic Breast Cancer, Progesterone Receptor Positive Tumor
A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer
The aim of this study is to increase, by DHA-induced chemosensitization, the activity of anticancer chemotherapy in patients with a metastatic advanced breast cancer, by a nutritional approach with marin-derived PolyUnsaturated…
- Conditions
- Metastatic Breast Cancer, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor, HER-2 Negative Tumor
- Trial name
- DHALYA (NCT01548534)
- Testing
- Dietary supplementation with fish oil., Dietary supplementation with vegetable oil
- Where
- 11 sites in France
- Volunteers
- 65 people
- Sponsor
- University Hospital, Tours
Breast Cancer, HER-2 Positive Breast Cancer
Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab
The purpose of this study is to evaluate the efficacy in terms of the pathological complete response (pCR) rate and the efficacy to preoperative administration of Anthracycline-based regimen followed by Nab-paclitaxel and…
- Conditions
- Breast Cancer, HER-2 Positive Breast Cancer, Effects of Chemotherapy
- Trial name
- NCT01432223
- Testing
- Nab-paclitaxel
- Where
- Japan
- Volunteers
- 46 people
- Sponsor
- Osaka Medical College
HER-2 Positive Metastatic Breast Cancer
UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer
This is a research study which aims to improve the way that doctors determine the dose of chemotherapy given to patients. Right now, chemotherapy is determined by a patient's height and weight.
- Trial name
- NCT00146042
- Testing
- Docetaxel, Trastuzumab, Erythromycin Breath Test (ERMBT)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Michigan Rogel Cancer Center
HER-2 Positive Breast Cancer
Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer
The purpose of the investigators study is to compare the efficacy and safety of combining trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy in Chinese HER2-positive breast cancer…
- Trial name
- NCT01428414
- Testing
- Trastuzumab, Paclitaxel, Epirubicin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhimin Shao
HER-2 Positive Breast Cancer
Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years
Main objective: To analyze the clinical and biological characteristics of patients with disseminated breast cancer HER2 + treated with trastuzumab that have achieved a complete remission, partial or stable disease for a period…
- Trial name
- LongHer (NCT01433926)
- Where
- 39 sites in Spain
- Volunteers
- 114 people
- Sponsor
- Asociación para el Progreso de la Oncología en Málaga